Clinical Trials Logo

Filter by:
NCT ID: NCT00410345 Completed - Abortion, Missed Clinical Trials

Cervical Rippening With Antiprogesterone in Midtrimester Abortions

Start date: August 2004
Phase: Phase 4
Study type: Interventional

Induction of midtrimester abortion includes cervical ripening and then contraction to induce uterine evacuation. There are several protocols, but most of them include using prostaglandins (PG). The disadvantages of using PG include uncomfortable side effects and limits of using it for women after cesarean section. Mifepristone is an antiprogesterone drug and been used for induction of abortion in first and second trimesters abortions. The aim of this study is to explore the effectiveness of Mifepristone for cervical ripening before high dose Oxytocin drip.

NCT ID: NCT00410332 Recruiting - Post-Tonsillectomy Clinical Trials

Traumeel for Post-Tonsillectomy Pain

Start date: March 2011
Phase: Phase 3
Study type: Interventional

Tonsillectomy is one the most common procedures in ear, nose and throat (ENT) medicine. Following surgery patients suffer from severe pain and difficulty on swallowing, while analgesic treatment has limited efficacy and potential adverse effects such as increased bleeding with NSAIDs. Traumeel S is a homeopathic complex remedy used primarily in Europe for the treatment of pain and inflammation. It contains a number of plants and minerals at high dilutions (between 1x10-2 to 1x10-8), and has been shown to exhibit anti-inflammatory properties such as cytokine inhibition in human T cells, monocytes and gut epithelial cells. Clinical studies have found Traumeel S reduces post-chemotherapy stomatitis, as well as post-surgical inflammation and pain following orthopedic procedures. The purpose of this study is to examine the effect of Traumeel S on post-tonsillectomy pain in adult patients. The study group will consist of 20 patients age 18 years of age and older following elective tonsillectomy. These patients will be randomly assigned to receive treatment with either true Traumeel S remedies or placebo. One ampule of Traumeel S (or placebo) will be sprayed over the resected area immediately following surgery. Two Traumeel S (or placebo) tablets will be taken subsequently 4 times daily (Total: 8 tablets per day)until no analgesics are required for 2 consecutive days, or until Day 14 (whichever comes first). Patients will be allowed to take dipyrone (Optalgin) 500mg tablets on an as-needed basis, for up to 14 days postoperatively. At the end of this period, a thorough ENT examination will be done. The primary parameter to be evaluated in the study will be postoperative pain, as registered on a numerical pain rating scale (NRS), to be filled prior to surgery. In the post-anesthesia care unit (PACA) the NRS will be filled out again, this time for pain at rest and then again for pain upon swallowing - at 1, 2, 3,4 and 24 hours postoperatively. Secondary parameters to be evaluated are: analgesic use (dipyrone); post-operative bleeding (quantified on a scale of 1-4); nocturnal awakenings; time to resumption of eating and return to normal activity; cytokine levels (CRP, IL-6) at 36 hours postoperative; and side effects of the treatment.

NCT ID: NCT00410137 Recruiting - Inflammation Clinical Trials

Influence of Nutritional and Inflammational Status on Survival of Hemodialysis Patients

Start date: March 2006
Phase: N/A
Study type: Observational

prospective longitudinal measurements of nutritional status parameters (body composition by BIA, anthropometry and biochemical indexes), inflammatory response (CRP, inflammatory cytokines (IL-1, IL-6, IL-10),IGF-1, leptin and NOx blood levels) and morbidity and mortality data collection over 2 year period in patients receiving chronic hemodialysis.

NCT ID: NCT00409526 Terminated - Clinical trials for Pulmonary Hypertension

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

Start date: December 2006
Phase: Phase 4
Study type: Interventional

Inhaled Iloprost will be administered to near term infants with Persistent Pulmonary Hypertension of the Newborn in two different doses in order to test safety and efficacy in reducing pulmonary artery pressure.

NCT ID: NCT00409227 Recruiting - Urolithiasis Clinical Trials

Does Treatment With Alfuzosin Increase Success Rates of (SWL) Shock Wave Lithotripsy

Start date: December 2006
Phase: Phase 2
Study type: Interventional

In latest literature more evidence is available about the positive effect of alpha blocker on stone expulsion from the ureter. Patients benefit from less pain and shortening time to stone expulsion. Our study is design to evaluate whether alfuzosin improves the stone free out come following SWL.

NCT ID: NCT00409201 Recruiting - Schizophrenia Clinical Trials

Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia

Start date: March 2006
Phase: Phase 1
Study type: Interventional

30 patients will randomly be selected and will be administered either reboxetine or a placebo. changes in cognition and behavior will be assessed by computer tests and scales during a six week study period.

NCT ID: NCT00409188 Completed - Clinical trials for Non-small Cell Lung Cancer

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

START
Start date: January 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether the cancer vaccine tecemotide (L-BLP25) in addition to best supportive care is effective in prolonging the lives of subjects with unresectable stage III non-small cell lung cancer, compared to best supportive care alone. A local ancillary (sub) study in European centers will evaluate the immune response in peripheral blood after tecemotide (L-BLP25) or placebo vaccination.

NCT ID: NCT00409162 Not yet recruiting - Healthy Clinical Trials

Safety and Efficacy Study of a New Device for Tattoo Removal

Start date: December 2006
Phase: N/A
Study type: Interventional

A new mechanical device is evaluated for tattoo removal, comparing two types of needle washing fluids. 30 healthy subjects with tattoos will be treated. The study hypothesis is that the device can be used to achieve satisfactory tattoo removal.

NCT ID: NCT00409149 Completed - Hypertension Clinical Trials

The Effect of a Complementary Multi Disciplinary Program on Blood Pressure in Hypertensive Patients

Start date: December 2006
Phase: Phase 3
Study type: Interventional

Intervention description: Complementary Approaches to Lower Mean arterial pressure (CALM) is a multi dispensary program aimed to reduce blood pressure in hypertensive patients. The program utilizes a naturopathic dietary approach, education on cooking and food consumption choices, walking physical exercise, Qi Gong - a form of Chinese slow movement exercise combined with relaxation breathing and imagery and group therapy coaching in stress management techniques and mind-body balancing techniques. Trial Objectives: To compare the effect of CALM in reducing blood pressure to the standard dietary DASH approach in hypertensive patients. Methodology: 120 Participants will be randomly assigned in to two groups: - CALM program for reducing blood pressure as the treatment group. - Standard DASH diet and lifestyle modification counseling as the control group. Inclusion Criteria - Adult men and women over 18 years. - Patients using anti hypertensive medications with mean systolic blood pressure measurements of 120-180 mm Hg and/or mean diastolic measurements of 70-100 mm Hg as determined by a 24 hour Holter test. - Patients not using anti hypertensive medications with mean systolic blood pressure measurements of 130-180 mm Hg and or mean diastolic measurements of 80-100 mmHg. - Signed informed consent (appears in IRB forms) Assessment of Efficacy Primary end point efficacy will be assessed by comparing the mean BP measurements in the CALM group to the mean BP measurements in the DASH control group. Blood pressure measurements will be performed by 24 hours Holter BP monitoring in the beginning and at the end of the trial. Secondary end points efficacy will be assed by comparing CALM to DASH programs with respect to effects use of BP medications and weight loss. Lab test and pulse wave analysis will also be assessed at the beginning and at the end of the study.

NCT ID: NCT00408759 Recruiting - Xerostomia Clinical Trials

Hypnosis for Treating Xerostomia Following Radiotherapy in Head & Neck Cancer Patients

Start date: November 2006
Phase: Phase 2
Study type: Interventional

xerostomia develops in all patients with head and neck cancer following radiotherapy. it consists one of the main side effects which affects quality of life. currently, there is no standard of care for treating this condition. parasympathomimetic drugs may help but carry significant side effects. hypnosis may affect autonomic function such as salivation, in healthy people.in this study we will explore the efficacy of hypnosis in improving salivation, in the patient population.